U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H23Cl2NO
Molecular Weight 328.277
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TESOFENSINE

SMILES

CCOC[C@H]1[C@H]2CC[C@@H](C[C@@H]1C3=CC(Cl)=C(Cl)C=C3)N2C

InChI

InChIKey=VCVWXKKWDOJNIT-ZOMKSWQUSA-N
InChI=1S/C17H23Cl2NO/c1-3-21-10-14-13(9-12-5-7-17(14)20(12)2)11-4-6-15(18)16(19)8-11/h4,6,8,12-14,17H,3,5,7,9-10H2,1-2H3/t12-,13+,14+,17+/m0/s1

HIDE SMILES / InChI
Tesofensine (also known as NS-2330) is a novel triple monoamine reuptake inhibitor with intrinsic inhibitory activity on norepinephrine (NE), serotonin (5-HT), and dopamine (DA) transporter function. It was development by NeuroSearch as a potential therapy for Alzheimer's disease (AD) and Parkinson's diseases, but these efforts have been discontinued. In phase II clinical trials with tesofensine in obese individuals, dose-related reductions in body weight, body fat and waist circumference, as well as improvements in other obesity-related endocrine factors were observed and the FDA recently endorsed the phase III trial program for this agent.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Disc. AE: Mood altered, syncope...
Other AEs: Nausea, vomiting...
AEs leading to
discontinuation/dose reduction:
Mood altered (8%)
syncope (2%)
Vertigo (2%)
Vertigo2 (16%)
Pain of skin (2%)
Hypervigilance (2%)
Ear and labyrinth disorders (2%)
Other AEs:
Nausea (22.4%)
vomiting (4.1%)
Dry mouth (59.2%)
Toothache (4.1%)
Abdominal pain (12.2%)
Diarrhoea (18.4%)
Constipation (16.3%)
Faeces hard (10.2%)
Faecaloma (6.1%)
Insomnia (16.5%)
Dyssomnia (2%)
Hypervigilance (6.1%)
Dizziness (12.2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Faeces hard 10.2%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Abdominal pain 12.2%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Dizziness 12.2%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Vertigo2 16%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Constipation 16.3%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Insomnia 16.5%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Diarrhoea 18.4%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Dyssomnia 2%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Ear and labyrinth disorders 2%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Hypervigilance 2%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Pain of skin 2%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Vertigo 2%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
syncope 2%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Nausea 22.4%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Toothache 4.1%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
vomiting 4.1%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Dry mouth 59.2%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Faecaloma 6.1%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Hypervigilance 6.1%
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
Mood altered 8%
Disc. AE
1 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1 mg, 1 times / day
Sources:
unhealthy
n = 49
Health Status: unhealthy
Condition: obesity
Sex: M+F
Food Status: UNKNOWN
Population Size: 49
Sources:
PubMed

PubMed

TitleDatePubMed
Chronic fluoxetine treatment induces brain region-specific upregulation of genes associated with BDNF-induced long-term potentiation.
2007
Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease.
2007 Feb 15
Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine.
2007 Jan 26
Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease.
2007 Jul
Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes.
2009 Aug 19
Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.
2009 Oct
Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
2010
[Recent progress and novel perspectives on obesity pharmacotherapy].
2010 Aug
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.
2010 Jul
Effect of centchroman coadministration on the pharmacokinetics of metformin in rats.
2010 Jun
Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.
2010 Jun
Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.
2010 Jun
The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant.
2010 Jun 25
Pharmacological management of appetite expression in obesity.
2010 May
New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?
2010 Nov
The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.
2010 Nov
Patents

Sample Use Guides

tesofensine 0.5 mg may cause almost double the weight loss
Route of Administration: Oral
In vitro investigations resulted in IC50 values for tesofensine of 11 and 1.7 nM for the [3 H]5-HT and [3 H]noradrenaline uptake, respectively.
Name Type Language
TESOFENSINE
INN   MART.   MI   WHO-DD  
INN  
Official Name English
NS2330
Code English
TESOFENSINE [MI]
Common Name English
tesofensine [INN]
Common Name English
Tesofensine [WHO-DD]
Common Name English
NS-2330
Code English
TESOFENSINE [MART.]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
FDA ORPHAN DRUG 804220
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
FDA ORPHAN DRUG 804320
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
Code System Code Type Description
WIKIPEDIA
Tesofensine
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY
ChEMBL
CHEMBL2107788
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY
EVMPD
SUB20754
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY
EPA CompTox
DTXSID70905114
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY
DRUG BANK
DB06156
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY
MESH
C518479
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY
MERCK INDEX
m10592
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY Merck Index
INN
8343
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY
PUBCHEM
11370864
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY
FDA UNII
BLH9UKX9V1
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY
CAS
195875-84-4
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY
NCI_THESAURUS
C66589
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY
SMS_ID
100000086513
Created by admin on Sat Dec 16 16:57:47 GMT 2023 , Edited by admin on Sat Dec 16 16:57:47 GMT 2023
PRIMARY